Cargando…
Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
OBJECTIVE: This study was to determine whether peripheral blood biomarkers including neutrophil‑lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) could predict early response to cetuximab; moreover, the prognostic ability of those biomarkers on pro...
Autores principales: | Jiang, Jinling, Ma, Tao, Xi, Wenqi, Yang, Chen, Wu, Junwei, Zhou, Chenfei, Wang, Nan, Zhu, Zhenggang, Zhang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767765/ https://www.ncbi.nlm.nih.gov/pubmed/31576170 http://dx.doi.org/10.2147/CMAR.S211089 |
Ejemplares similares
-
A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer
por: Shi, Min, et al.
Publicado: (2020) -
Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016) -
Postoperative BMI Loss at One Year Correlated with Poor Outcomes in Chinese Gastric Cancer Patients
por: Wang, Nan, et al.
Publicado: (2020) -
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007) -
First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)